GE Board of Directors Authorizes Regular Quarterly Dividend
BOSTON, June 21, 2019 (GLOBE NEWSWIRE) -- The Board of Directors of GE (NYSE: GE) today declared a $0.01 per share dividend on the outstanding common stock of the Company. The dividend is payable July 25, 2019 to shareowners of record at the close of business on July 1, 2019. The ex-dividend date is June 28, 2019.
About GE
GE (NYSE:GE) drives the world forward by tackling its biggest challenges. By combining world-class engineering with software and analytics, GE helps the world work more efficiently, reliably, and safely. For more than 125 years, GE has invented the future of industry, and today it leads new paradigms in additive manufacturing, materials science, and data analytics. GE people are global, diverse and dedicated, operating with the highest integrity and passion to fulfill GE's mission and deliver for our customers.
www.ge.com
GE's Investor Relations website at www.ge.com/investor and our corporate blog at www.ge.com/reports and @GE_Reports on Twitter, as well as GE's Facebook page and Twitter accounts, contain a significant amount of information about GE, including financial and other information for investors. GE encourages investors to visit these websites from time to time, as information is updated and new information is posted.
GE Investor Contact:
Steve Winoker, 617.443.3400
swinoker@ge.com
GE Media Contact:
Jennifer Erickson, 646.682.5620
jennifer.erickson@ge.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mohawk Industries Reports Q1 Results25.4.2024 22:10:00 CEST | Press release
CALHOUN, Ga., April 25, 2024 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced first quarter 2024 net earnings of $105 million and earnings per share (“EPS”) of $1.64; adjusted net earnings were $119 million, and adjusted EPS was $1.86. Net sales for the first quarter of 2024 were $2.7 billion, a decrease of 4.5% as reported and 5.5% on a legacy and constant basis versus the prior year. During the first quarter of 2023, the Company reported net sales of $2.8 billion, net earnings of $80 million and EPS of $1.26; adjusted net earnings were $112 million, and adjusted EPS was $1.75. Commenting on the Company’s first quarter results, Chairman and CEO Jeff Lorberbaum stated, “Though economic headwinds are impacting industry sales, margins and mix, our first quarter results reflected the positive effect of actions we are taking to enhance our performance. Our earnings per share rose year over year as a result of restructuring, productivity initiatives and benefits from
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®25.4.2024 22:05:00 CEST | Press release
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19. The CHMP’s positive opinion will now be referred to the European Commission (EC), which will decide whether to grant marketing authorization for TOFIDENCE. If a marketing authorization is granted by the EC, TOFIDENCE will be an addition to the existing biosimilars portfolio of three widely p
WillScot Mobile Mini Announces Investor Conference Schedule for May and June 202425.4.2024 22:01:00 CEST | Press release
PHOENIX, April 25, 2024 (GLOBE NEWSWIRE) -- WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that it will participate in the following investor conferences in the coming months: Oppenheimer Industrial Growth Conference Date: May 6, 2024 Location: Virtual Barclays Americas Select Franchise Conference Date: May 7 - 8, 2024 Location: London, UK Bank of America Transportation, Airlines, and Industrials Conference Date: May 15, 2024 Location: New York, NY William Blair Growth Stock Conference Date: June 4, 2024 Location: Chicago, IL Stifel Cross Sector Insights Date: June 4, 2024 Location: Boston, MA Baird Global Consumer, Tech & Services Conference Date: June 5, 2024 Location: New York, NY Deutsche Bank Industrials Conference Date: June 6, 2024 Location: New York, NY Wells Fargo Industrials Conference Date: June 11, 2024 Location: Chicago, IL Portfolio managers and analysts who wis
Nokia Corporation: Repurchase of own shares on 25.04.202425.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 25 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 25.04.2024 Espoo, Finland – On 25 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL413,2473.38CEUX--BATE--AQEU--TQEX--Total413,2473.38 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of
LEADING EDGE MATERIALS ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS25.4.2024 20:59:00 CEST | Press release
LEADING EDGE MATERIALS ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Vancouver, April 25, 2024 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) announces the results of the Company’s Annual General Meeting of Shareholders held on April 25, 2024 (the “Meeting”). A total of 84,326,601 common shares were represented in person or by proxy at the Meeting, representing 44.16% of the votes attached to all outstanding common shares of the Company as at the record date. All the matters submitted to the shareholders, as set out in the Notice of Meeting and Information Circular dated March 19, 2024, were voted in favour, including: (a) fixing the size of the Board of the Company to three; (b) the approval of the stock options plan, pursuant to which the Company may grant stock options up to 10% of its issued and outstanding common shares at the time of grant; and (c) the appointment of D&H Gr